Clinical Trials Logo

Filter by:
NCT ID: NCT01410552 Completed - Tachycardia Clinical Trials

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

ISIS-ICD
Start date: October 2011
Phase: N/A
Study type: Interventional

ISIS- ICD study has been designed to evaluate the impact of PARAD+ algorithm on inappropriate shocks, in a general population implanted for primary or secondary prevention with a dual or tri chamber device at one year follow-up

NCT ID: NCT01410227 Completed - Clinical trials for Von Willebrand Disease

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Start date: November 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this Phase 3 study is to assess the pharmacokinetics of rVWF:rFVIII and rVWF, and to assess the safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding events in subjects with severe hereditary von Willebrand disease (VWD).

NCT ID: NCT01409356 Completed - Obesity Clinical Trials

Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis

SPORTDIET
Start date: October 2011
Phase: Phase 2
Study type: Interventional

Overweight/obesity is increasing both in the general population and in patients with cirrhosis. In compensated patients with cirrhosis increased BMI is a risk factor for clinical decompensation independent of liver function and portal pressure. Nonetheless, patients with cirrhosis and obesity show a progressive increase in portal pressure, which might explain their increased risk of complications. Since obesity is a potentially modifiable risk factor, we designed this proof-of-concept study to assess the effects of weight loss (obtained by 4 months of diet and exercise) on portal pressure in patients with compensated cirrhosis and overweight/obesity.

NCT ID: NCT01408966 Completed - Cirrhosis Clinical Trials

Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This study was aimed at testing the hypothesis that supplementing a meal with dark chocolate, which holds potent antioxidant properties, might attenuate the postprandial increase in the hepatic venous pressure gradient (HVPG, clinical equivalent of portal pressure) in patients with cirrhosis

NCT ID: NCT01408576 Completed - Clinical trials for Systemic Lupus Erythematosus

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

EMBODY4
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)

NCT ID: NCT01408381 Completed - Clinical trials for Critical Limb Ischemia (CLI)

Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).

Start date: January 2011
Phase: Phase 2
Study type: Interventional

Phase II Clinical Trial, a prospective, multicenter, open, randomized, parallel-group controlled with three levels of dose. The hypothesis of the test we propose is that the mononuclear cells of bone marrow provide progenitor cells with regenerative capacity and besides secrete several angiogenic factors, and their implantation into ischemic tissues with both elements should contribute to angiogenesis and tissue regeneration with recovery of the circulation in the affected limb.

NCT ID: NCT01408238 Completed - Clinical trials for Allergy to Grass Pollen (Secale Cereale)

Biological Standardization of Secale Cereale Allergen Extract

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the biologic activity of a Secale cereale allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

NCT ID: NCT01408199 Completed - Cutaneous Lupus Clinical Trials

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

ORDI-02
Start date: January 2010
Phase: Phase 4
Study type: Interventional

Cutaneous Lupus is frequent. Approximately 70% of patients with SLE will develop cutaneous involvement at some point during course of their disease. In spite of the esthetic consequence during the acute phase, the main problem is still related to its disfiguring and incapacitating nature. Topical steroids and/or antimalarial therapy continue to be the conventional therapy. Unfortunately, approximately 30% will be refractory to these measures. For those patients, immunosuppressive therapy can be an alternative with controversial results. Several series have shown a 90% of clinical efficacy in patients treated with Thalidomide. Unfortunately, the main drawback has been the serious described side effects such as fetal malformations, polyneuropathy and drowsiness. Recently, a new thalidomide analogue, more potent, efficient and with better safety profile has been discovered. The main objective of the study is to evaluate the efficacy and safety of Lenalidomide for patients with Refractory cutaneous Lupus. Secondary objectives include evaluating the effect of this drug on the systemic manifestations of lupus disease, the adverse effects, frequency of flare after withdrawal, the sequela and the effect on the seric parameters. Methods: Twelve patients with refractory cutaneous lupus will be included. Lenalidomide will be started at 5mg/day and tapered progressively. Blood test and EMG will be performed at onset and at the end of follow up.

NCT ID: NCT01407835 Completed - Clinical trials for Allergy to Grass Pollen (Dactylis Glomerata)

Biological Standardization of Dactylis Glomerata Allergen Extract

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the biologic activity of a Dactylis glomerata allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

NCT ID: NCT01407159 Completed - Clinical trials for Type B Aortic Dissection

A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting

ASSIST
Start date: November 2011
Phase: N/A
Study type: Observational

Cohort study according to national regulatory guidelines: Non-interventional, observational cohort study. Pair-matched comparison with patients chosen from historical series. To evaluate the clinical and technical success as well as the safety and feasibility of the E-XL aortic stent used in complicated type B aortic dissection in addition to a classic stentgraft in a single procedure.